Skip to main content Skip to main navigation menu Skip to site footer

The presence of stem cells in ovarian cancer: a review

  • Tricia Dewi Anggraeni ,
  • Jenivia Thiono ,
  • Intan Winta Pratiwi ,
  • Ariananda Hariadi ,
  • Tera Dria Kispa ,
  • Aria Kekalih ,
  • Brahmana Askandar ,
  • Lisnawati ,
  • Ani Retno Prijanti ,
  • Mohamad Farid Aziz ,
  • Hariyono Winarto ,
  • Marselina Irasonia Tan ,
  • Andrijono ,

Abstract

Ovarian cancer is one of the deadly gynecological malignancies. The disease has usually difficult to detect at the early stage as there are only a few specific symptoms and not many screening methods, thus patients usually come in an advanced and metastatic stage of the disease. Initial therapy for the disease includes surgery to remove the tumor, then followed by chemotherapy. This therapy shows a promising result at first until some sign of reoccurrence starts to show. One of the main reasons is thought to be the presence of a small subset of cells called cancer stem cells (CSCs). These cells may escape from the initial therapy, and due to the CSCs' ability to self-renew, grow into various lineages, and multiply widely. There are multiple efforts done to isolate and identify this subset cell, such as identifying the specific antigen in the cell surface, using Side Population, the ability of CSCs to form floating spheres in serum-free media, and the level of ALDH expression. Such methods have been performed together to identify purely cancer stem cells from the malignancy. The ability of the cell to produce new tumors in immuno-deficient animals, however, is the gold standard for identifying CSC, according to the current study. This review will discuss several methods that have been used to isolate cancer stem cells and prove the stemness of these cells by injecting them into immuno-deficient mice. Cancer stem cells also can avoid the effect of chemotherapy. Several things contribute to this ability. This review there will discuss methods that have been several things that make it possible to be able to escape chemotherapy drugs. By understanding these mechanisms, hopefully, new therapy modalities will be developed and specifically targeted, so that can be used to treat malignancies more effectively.

References

  1. USCS Data Visualizations [Internet]. Gis.cdc.gov. 2019 [cited 19 June 2019]. Available from: https://gis.cdc.gov/Cancer/USCS/DataViz.html
  2. Garson K, Vanderhyden B. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. REPRODUCTION. 2015;149(2):R59-R70.
  3. Huang Y, Ju B, Tian J, Liu F, Yu H, Xiao H et al. Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening. Oncology Reports. 2014;31(3):1235-1248.
  4. Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M. Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. International Journal of Clinical and Experimental Medicine. 2015;8(3):3080-3088.
  5. Bapat S. Human ovarian cancer stem cells. REPRODUCTION. 2010;140(1):33-41.
  6. Shi M, Jiao J, Lu W, Ye F, Ma D, Dong Q et al. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cellular and Molecular Life Sciences. 2010;67(22):3915-3925.
  7. Muinao T, Deka Boruah H, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review. 2019.
  8. Fong M, Kakar S. The role of cancer stem cells and the side population in epithelial ovarian cancer. Histology and Histopathology Cellular and Molecular Biology. 2015;25:113-120.
  9. Birrer M, Ceppi L. Translational advances in gynecologic cancers. United States: Elsevier; 2017.
  10. Witt A, Lee C, Lee T, Azzam D, Wang B, Caslini C et al. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2016;36(12):1707-1720.
  11. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo J et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer. 2012;12(11):767-775.
  12. Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A. Cancer stem cells: The root of tumor recurrence and metastases. 2017.
  13. Jordan C, Guzman M, Noble M. Cancer Stem Cells. The New England Journal of Medicine. 2006;355(12):1253-61.
  14. Abdullah L, Chow E. Mechanisms of chemoresistance in cancer stem cells. Clinical and Translational Medicine. 2013;2(1):3.
  15. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences. 2003;100(7):3983-3988.
  16. Vathipadiekal V, Saxena D, Mok S, Hauschka P, Ozbun L, Birrer M. Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer. PLoS ONE. 2012;7(1):e29079.
  17. Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R. Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. Molecular Cancer. 2017;16(1).
  18. Aguilar-Gallardo C, Simón C. Cells, Stem Cells, and Cancer Stem Cells. 2013.
  19. Rich J. Cancer stem cells: understanding tumor hierarchy and heterogeneity. 2016.
  20. Ahmed N, Abubaker K, Findlay J. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. 2013.
  21. Ng A, Barker N. Ovary and fimbrial stem cells: biology, niche and cancer origins. Nature Reviews Molecular Cell Biology. 2015;16(10):625-638. (Ovary and fimbrial stem cells niche)
  22. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res.2004;64(19):7011–21.
  23. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005;65(14):6207–19.
  24. Moghbeli M, Moghbeli F, Forghanifard M, Abbaszadegan M. Cancer stem cell detection and isolation. Medical Oncology. 2014;31(9).
  25. Szotek PP, Pieretti-Vanmarke R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A 2006;103:11154–9.
  26. Papaccio G, Desiderio V. Cancer stem cells. 1st ed. New York: Springers; 2018.
  27. Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W et al. Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biology International. 2011;35(3):227-234.
  28. Curley M, Therrien V, Cummings C, Sergent P, Koulouris C, Friel A et al. CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. Stem Cells. 2009;27:2875-2883
  29. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A et al. Expression of CD133-1 and CD133-2 in ovarian cancer. International Journal of Gynecologic Cancer. 2008;18(3):506-514.
  30. Liu T, Lai D, Cheng W, Huang Y, Guo L. Characterization of primary ovarian cancer cells in different culture systems. Oncology Reports. 2010;23(5).
  31. Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z et al. Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE.
  32. He Q, Luo X, Wang K, Zhou Q, Ao H, Yang Y et al. Isolation and Characterization of Cancer Stem Cells from High-Grade Serous Ovarian Carcinomas. Cellular Physiology and Biochemistry. 2014;33(1):173-184.
  33. Oliveira LR: Stem cells and cancer stem cells. In Cancer Stem Cells – The Cutting Edge. Edited by Shostak S. Rijeka: InTech; 2011:3–28.
  34. Zhan Q, Wang C, Ngai S. Ovarian Cancer Stem Cells: A New Target for Cancer Therapy. 2013.
  35. Yasuda K, Torigoe T, Morita R, Kuroda T, Takahashi A, Matsuzaki J et al. Ovarian Cancer Stem Cells Are Enriched in Side Population and Aldehyde Dehydrogenase Bright Overlapping Population. PLoS ONE. 2013;8(8):e68187.
  36. Longley D, Johnston P. Molecular mechanisms of drug resistance. The Journal of Pathology. 2005;205(2):275-292.
  37. Abdullah L, Chow E. Mechanisms of chemoresistance in cancer stem cells. Clinical and Translational Medicine. 2013;2(1):3.
  38. Hu X, Macdonald D, Huettner P, Feng Z, El Naqa I, Schwarz J et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology. 2009;114(3):457-464.
  39. Di Leva G, Croce C. The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Frontiers in Oncology. 2013;3.
  40. Thomas M, Coyle K, Sultan M, Kashani A, Marcato P. Chemoresistance in Cancer Stem Cells and Strategies to Overcome Resistance. Chemotherapy: Open Access. 2014;03(01).
  41. Moore N, Lyle S. Quiescent, Slow-Cycling Stem Cell Populations in Cancer: A Review of the Evidence and Discussion of Significance. Journal of Oncology. 2011;2011:1-11.
  42. Weber A, Ryan A. ATM and ATR as therapeutic targets in cancer. 2014.

How to Cite

Anggraeni, T. D., Thiono, J., Pratiwi, I. W., Hariadi, A., Kispa, T. D., Kekalih, A., Askandar, B., Lisnawati, Prijanti, A. R., Mohamad Farid Aziz, Winarto, H., Tan, M. I., & Andrijono. (2023). The presence of stem cells in ovarian cancer: a review. Bali Medical Journal, 12(1), 1001–1008. https://doi.org/10.15562/bmj.v12i1.4011

HTML
4

Total
1

Share

Search Panel